Hospital
Mountain Vista Medical Center, LP
Mountain Vista Medical Center, LP was paid $8.21M by Medicaid between Sep 2019 and Sep 2024, across 109 billing codes. Its largest line is 99285, emergency room visit (most serious) — 27% of everything it billed.
33Billing provider infoMOUNTAIN VISTA MEDICAL CENTER, LP
FLORENCE, AZ 85132
FLORENCE, AZ 85132
33aNPI1609345685assigned 11/19/2018
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.21M
24GClaims166,432
24DCodes billed109
24AFirst – last monthSep 2019 – Sep 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#45 of 78
Median peer was paid$12.21M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 7,293 | $164K | |
| 2020 | 26,503 | $980K | |
| 2021 | 34,782 | $1.63M | |
| 2022 | 41,034 | $2.28M | |
| 2023 | 34,046 | $1.92M | |
| 2024incomplete | 22,774 | $1.24M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 27% | 7,457 | 6,561 | $2.25M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 8,749 | 8,218 | $1.52M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 9,002 | 8,448 | $1.36M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 14% | 1,494 | 1,381 | $1.16M |
| 80053 | Comprehensive metabolic panel | 8.0% | 8,378 | 7,093 | $658K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 7.9% | 1,105 | 1,027 | $648K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 1,788 | 1,664 | $119K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 766 | 734 | $113K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 1,839 | 1,694 | $89K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 119 | 116 | $44K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 590 | 576 | $39K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,985 | 3,556 | $39K |
97 more codes
| 73610 | <1% | 134 | $27K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 303 | $23K |
| 73562 | <1% | 86 | $20K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 364 | $19K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 973 | $16K |
| 73130 | <1% | 74 | $15K | |
| 73630 | <1% | 100 | $13K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,921 | $9K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 228 | $7K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 40 | $6K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 37 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 219 | $4K |
| 73110 | <1% | 15 | $2K | |
| 80050 | General health panel | <1% | 14 | $1K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,858 | $539.27 |
| 71045 | Radiologic examination, chest; single view | <1% | 4,882 | $537.24 |
| 87186 | <1% | 607 | $484.18 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,904 | $483.23 |
| 87428 | <1% | 2,878 | $422.74 | |
| 73030 | <1% | 26 | $353.86 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 461 | $316.79 |
| 74022 | <1% | 12 | $302.75 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,351 | $246.57 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,506 | $187.46 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,647 | $183.40 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,936 | $174.75 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,765 | $96.45 |
| 74018 | <1% | 557 | $81.54 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,754 | $80.46 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,434 | $80.23 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,520 | $48.25 |
| 83605 | <1% | 971 | $47.70 | |
| 81025 | <1% | 2,201 | $45.50 | |
| 84484 | <1% | 3,651 | $42.02 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,872 | $37.24 |
| 83690 | <1% | 3,045 | $35.44 | |
| 83880 | <1% | 647 | $30.15 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,002 | $25.56 |
| 81001 | <1% | 4,063 | $24.23 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,207 | $23.60 |
| 85027 | <1% | 783 | $23.27 | |
| 82550 | <1% | 462 | $22.80 | |
| 94760 | <1% | 242 | $20.11 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,292 | $19.68 |
| 83735 | <1% | 2,763 | $19.42 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,016 | $18.42 |
| 87088 | <1% | 128 | $16.72 | |
| 82077 | <1% | 235 | $12.44 | |
| 81003 | <1% | 3,204 | $12.19 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,143 | $10.92 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 875 | $10.38 |
| 85610 | <1% | 992 | $8.86 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,546 | $8.85 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,220 | $7.14 |
| 82962 | <1% | 731 | $6.60 | |
| 87081 | <1% | 2,070 | $6.29 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 972 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,218 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 38 | $0.00 |
| 96376 | 0% | 1,144 | $0.00 | |
| G0378 | Hospital observation service, per hour | 0% | 296 | $0.00 |
| 87807 | 0% | 464 | $0.00 | |
| 84703 | 0% | 1,386 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 206 | $0.00 |
| 80320 | 0% | 171 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 262 | $0.00 |
| 87040 | 0% | 315 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 159 | $0.00 |
| 85379 | 0% | 261 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 12 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 133 | $0.00 |
| 71275 | Computed tomographic angiography, chest, with contrast material | 0% | 67 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 268 | $0.00 |
| 87147 | 0% | 59 | $0.00 | |
| 94761 | 0% | 15 | $0.00 | |
| 87077 | 0% | 14 | $0.00 | |
| 85730 | 0% | 14 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 26 | $0.00 |
| 80047 | 0% | 12 | $0.00 | |
| 93971 | 0% | 13 | $0.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 12 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 13 | $0.00 |
| 12001 | 0% | 13 | $0.00 | |
| 84702 | 0% | 73 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 636 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 947 | $0.00 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 0% | 508 | $0.00 |
| 80143 | 0% | 99 | $0.00 | |
| 80179 | 0% | 99 | $0.00 | |
| 82947 | 0% | 95 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 48 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 27 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 28 | $0.00 |
| 90715 | 0% | 26 | $0.00 | |
| 93976 | 0% | 19 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 12 | $0.00 |
| 84600 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGOLICH, JACOB (HOSPITAL PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Mountain Vista Medical Center LP | Mesa, AZ | $20.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.